Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Year ended December 31, 2023
Filing Date: June 17, 2024
This filing serves to re-issue the Company's consolidated financial statements for the year ended December 31, 2023, following a change in accounting standards. The Company transitioned from International Financial Reporting Standards (IFRS) to U.S. Generally Accepted Accounting Principles (U.S. GAAP) effective January 1, 2024. These re-issued statements replace those previously included in the Annual Report on Form 20-F filed on April 4, 2024.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. The actual financial figures are located in the attached exhibits (Exhibit 99.1) which are referenced but not included in the input text.
Material Changes
- Accounting Method Change: The Company changed its accounting method from IFRS to U.S. GAAP as of January 1, 2024.
- Restatement: Consolidated financial statements for the year ended December 31, 2023, have been re-issued to comply with U.S. GAAP.
- Document Replacement: The re-issued statements and the accompanying Operating and Financial Review and Prospects (Exhibit 99.2) supersede the documents filed in the April 4, 2024 Form 20-F.
Guidance, Outlook, and Risks
The text references an "Operating and Financial Review and Prospects" attached as Exhibit 99.2, but the content of this section is not present in the provided input. Consequently, no specific guidance, management commentary, risks, or contingencies can be summarized from this text alone.
Investor Verification Checklist
- Verify the specific financial impact of the transition from IFRS to U.S. GAAP by reviewing Exhibit 99.1 (Consolidated Financial Statements).
- Compare the re-issued December 31, 2023 financials against the original April 4, 2024 Form 20-F to identify material variances in reported metrics.
- Review Exhibit 99.2 for updated management discussion regarding the Company's prospects and liquidity position under U.S. GAAP.
- Confirm the consent of the independent registered accounting firm (Exhibit 99.3) regarding the restated financials.